Parkman Healthcare Partners LLC Makes New Investment in Stryker Corporation $SYK

Key Points

• Parkman Healthcare Partners initiated a position in Stryker during the second quarter, buying 67,973 shares valued at approximately $21.4 million. Stryker now represents 2.2% of the firm’s portfolio.
• Stryker reported quarterly EPS of $3.69, exceeding the $3.49 analyst consensus, while revenue rose 9.4% year over year to $6.59 billion. The company maintained fiscal 2026 EPS guidance of $14.95 to $15.10.
• Insiders sold about 355,370 shares worth $119.4 million during the last quarter, including a $100.8 million sale by director Ronda E. Stryker. Despite the selling, analysts give the stock a consensus “Moderate Buy” rating with an average price target of $386.28.

Parkman Healthcare Partners LLC purchased a new position in Stryker Corporation (NYSE:SYK - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 67,973 shares of the medical technology company's stock, valued at approximately $21,401,000. Stryker accounts for 2.2% of Parkman Healthcare Partners LLC's portfolio, making the stock its 14th largest holding.

Several other institutional investors and hedge funds have also made changes to their positions in SYK. VanderPol Investments L.L.C. increased its stake in shares of Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock valued at $732,000 after acquiring an additional 28 shares during the period. KCM Investment Advisors LLC lifted its position in Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock worth $653,000 after purchasing an additional 28 shares during the period. Rossby Financial LCC boosted its stake in Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock valued at $159,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC boosted its stake in Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock valued at $403,000 after purchasing an additional 29 shares in the last quarter. Finally, ICW Investment Advisors LLC increased its position in shares of Stryker by 0.6% during the 4th quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company's stock valued at $1,791,000 after purchasing an additional 30 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 300,000 shares of the firm's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. This trade represents a 11.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Debra King sold 826 shares of Stryker stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 355,370 shares of company stock valued at $119,447,201. 4.60% of the stock is owned by corporate insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $327.80 on Tuesday. The company has a market capitalization of $125.73 billion, a PE ratio of 33.97, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The stock has a fifty day moving average of $327.39 and a 200-day moving average of $332.16. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company's quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Wolfe Research downgraded Stryker from an "outperform" rating to a "peer perform" rating in a research note on Thursday, August 13th. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Canaccord Genuity Group lowered their target price on Stryker from $435.00 to $400.00 and set a "buy" rating on the stock in a report on Friday, May 1st. Barclays dropped their price target on shares of Stryker from $469.00 to $394.00 and set an "overweight" rating on the stock in a research report on Monday, May 4th. Finally, Truist Financial raised their price objective on shares of Stryker from $330.00 to $340.00 and gave the company a "hold" rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source